Table 1. Clinical characteristics of survivors and nonsurvivors.
| Survivors (n = 19) | Nonsurvivors (n = 17) | p value | |
|---|---|---|---|
| Age, yrs | 73.9±6.6 | 73.1±7.1 | 0.74 |
| Sex (male/female) | 16/3 | 15/2 | 0.72 |
| Brinkman index | 678.4±436.8 | 741.2.0±663.4 | 0.74 |
| P/F ratio | 256.1±99.9 | 214.7±87.0 | 0.20 |
| CRP (mg/dl) | 6.6±5.1 | 10.5±7.0 | 0.06 |
| APACHE II score | 12.1±4.4 | 14.7±7.4 | 0.24 |
| LDH (IU/l) | 344.7±103.4 | 407.2±115.7 | 0.10 |
| KL-6 (U/ml) | 1895.2±2331.7 | 1346.6±700.5 | 0.46 |
| SP-D (ng/ml) | 375.1±319.7 | 547.9±339.1 | 0.13 |
| D-dimer (μg/ml) | 9.2±13.2 | 11.2±9.6 | 0.63 |
| HMGB1, day 0 (ng/ml) | 14.7±12.9 | 9.5±4.1 | 0.15 |
| rhTM use (number [%]) | 15/19 (78.9%) | 10/17 (58.8%) | 0.19 |
| CsA use (number [%]) | 17/19 (89.5%) | 9/17 (52.9%) | 0.02 |
| HRCT pattern at the onset of AE Peripheral -multifocal/diffuse | 13/6 | 6/11 | 0.04 |
CRP: C-reactive protein; LDH: lactate dehydrogenase; SP-D: surfactant protein-D; P/F ratio: PaO2 /FiO2 ratio, AE: acute exacerbation, CsA: Cyclosporine A